Baricitinib
Brief hiatus in baricitinib therapy led to minor RA symptom recurrence
Baricitinib receives breakthrough therapy designation for alopecia areata
Baricitinib achieves primary endpoint in BREEZE-AD4, BREEZE-AD5 studies
Baricitinib plus topical steroids improves atopic dermatitis symptoms
Glenmark receives FDA approval for generic atopic dermatitis cream
VIDEO: Benefits, concerns of JAK inhibitor use in RA
In this video, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed the current state of JAK inhibitors as a newer development in RA treatment, and her approach towards prescribing them in the face of concerns about side effects.
VIDEO: Baricitinib approval ‘major breakthrough’ for alopecia areata
VIDEO: Alopecia areata ‘still a challenging disease’ despite available treatments
In this video,Carolyn Goh, MD, clinical associate professor in dermatology at David Geffen School of Medicine at UCLA, discusses the biggest challenges in alopecia areata care, including the lack treatment options for pediatric patients and the difficulty in obtaining insurance coverage for treatments.